Summary of recent studies of cord HSCT for SAA
| Reference . | N . | Median age (range), y . | Conditioning regimen . | Engraftment (neutrophils and platelets) . | aGVHD (Gd II-IV) or cGVHD (cumulative incidence) . | OS . |
|---|---|---|---|---|---|---|
| Delatour et al25 | 71: single, n = 57; double, n = 14 | 13 (2-68) | RIC (Flu-based) 68%; myeloablative 31% | Median time for NE 25 d and PE 45 d; CI of neutrophil recovery 51% ± 6%; platelet recovery 37% ± 7% | aGVHD 20% ± 5%; cGVHD 18% ± 5% | 3 y OS 38% ± 6% |
| Kosaka et al12 | 31 | 28 (1-72) | TBI + Mel + Flu (n = 12); TBI + CY + Flu (n = 5); TBI + CY + ATG (n = 3); others (n = 11) | Median time for NE 19 d and PE 59 d; CI of neutrophil recovery 55%; platelet recovery 72% | aGVHD 17%; cGVHD 20% | 2 y OS 41% (6%-33%) |
| Yamamoto et al26 | 12 | 49 (20-70) | RIC; Flu + Mel + TBI (4 Gy) | Median time for NE 18 d and PE 42 d; 11/12 engrafted | aGVHD 5/11 (all Gd 2) cGVHD 3/9 (all limited) | 3 y OS 83% |
| Liu et al44 | 18 | 17 (5-61) | RIC; Flu + CY + ATG | Median time for NE 37 d and PE 87 d; 1/16 engrafted | None reported | 2 y OS 89% |
| Reference . | N . | Median age (range), y . | Conditioning regimen . | Engraftment (neutrophils and platelets) . | aGVHD (Gd II-IV) or cGVHD (cumulative incidence) . | OS . |
|---|---|---|---|---|---|---|
| Delatour et al25 | 71: single, n = 57; double, n = 14 | 13 (2-68) | RIC (Flu-based) 68%; myeloablative 31% | Median time for NE 25 d and PE 45 d; CI of neutrophil recovery 51% ± 6%; platelet recovery 37% ± 7% | aGVHD 20% ± 5%; cGVHD 18% ± 5% | 3 y OS 38% ± 6% |
| Kosaka et al12 | 31 | 28 (1-72) | TBI + Mel + Flu (n = 12); TBI + CY + Flu (n = 5); TBI + CY + ATG (n = 3); others (n = 11) | Median time for NE 19 d and PE 59 d; CI of neutrophil recovery 55%; platelet recovery 72% | aGVHD 17%; cGVHD 20% | 2 y OS 41% (6%-33%) |
| Yamamoto et al26 | 12 | 49 (20-70) | RIC; Flu + Mel + TBI (4 Gy) | Median time for NE 18 d and PE 42 d; 11/12 engrafted | aGVHD 5/11 (all Gd 2) cGVHD 3/9 (all limited) | 3 y OS 83% |
| Liu et al44 | 18 | 17 (5-61) | RIC; Flu + CY + ATG | Median time for NE 37 d and PE 87 d; 1/16 engrafted | None reported | 2 y OS 89% |
Flu indicates fludarabine; NE, neutrophil engraftment; PE, platelet engraftment; and CI, cumulative incidence.